论文部分内容阅读
位于肿瘤细胞表面的免疫球蛋白(Ig)具有独特性(独特型,Id),可为免疫系统识别.动物和人体试验表明,抗独特型单克隆抗体可使肿瘤消退,但可能会因为编码独特型抗原决定簇的基因突变而使肿瘤逃逸.接种源于肿瘤细胞的独特型疫苗可以避免此种情况发生,并且可诱生多克隆抗体和T细胞免疫应答,保护动物免受肿瘤的攻击,为此,作者对肿瘤特异性独特型疫苗治疗B细胞淋巴瘤的疗效进行了临床研究.作者选取了41例非何杰金B细胞淋巴瘤患者,每个病人都行淋巴结活检获取肿瘤细胞.将肿瘤细胞与K6H6B5细胞融合制备Ig,利用免疫学和分子生物学方法筛选与肿瘤基因型相配的Ig.将Ig用亲和层析纯化
The immunoglobulin (Ig) located on the surface of tumor cells is unique (idiotype, Id) and can be recognized by the immune system. Animal and human trials have shown that anti-idiotypic monoclonal antibodies can cause tumor regression, but may be unique due to unique coding Mutations in the type of antigenic determinant make the tumor escape. Inoculation of the idiotype vaccine derived from tumor cells can prevent this from happening, and can induce polyclonal antibodies and T cell immune responses to protect animals from tumor attacks. Therefore, the authors performed a clinical study on the efficacy of tumor-specific idiotype vaccines in the treatment of B-cell lymphoma. The authors selected 41 patients with non-Hodgkin’s B-cell lymphoma. Each patient underwent lymph node biopsy to obtain tumor cells. Cells are fused with K6H6B5 cells to produce Ig. Immunological and molecular biological methods are used to screen for Ig that matches the tumor genotype. Ig is purified by affinity chromatography.